Skip to content

BASP1 interacts with estrogen receptor α and modifies the tamoxifen response

Research output: Contribution to journalArticle

Original languageEnglish
Article numbere2771
Number of pages10
JournalCell Death and Disease
Volume8
Issue number5
DOIs
DateAccepted/In press - 14 Mar 2017
DatePublished (current) - 11 May 2017

Abstract

Tamoxifen binds to estrogen receptor α (ERα) to elicit distinct responses that vary by cell/tissue type and status, but the factors that determine these differential effects are unknown. Here we report that the transcriptional corepressor BASP1 interacts with ERα and in breast cancer cells, this interaction is enhanced by tamoxifen. We find that BASP1 acts as a major selectivity factor in the transcriptional response of breast cancer cells to tamoxifen. 40% of the genes that are regulated by tamoxifen in breast cancer cells are BASP1-dependent, including several genes that are associated with tamoxifen resistance. BASP1 elicits tumour-suppressor activity in breast cancer cells and enhances the anti-tumourigenic effects of tamoxifen treatment. Moreover, BASP1 is expressed in breast cancer tissue and is associated with increased patient survival. Our data has identified BASP1 as an ERα cofactor that plays a central role in the transcriptional and anti-tumourigenic effects of tamoxifen.

    Research areas

  • BASP1, Estrogen receptor, ERα, Tamoxifen, Breast cancer, Transcription

Download statistics

No data available

Documents

Documents

  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Nature at https://doi.org/10.1038/cddis.2017.179 . Please refer to any applicable terms of use of the publisher.

    Final published version, 1 MB, PDF document

    Licence: CC BY

DOI

View research connections

Related faculties, schools or groups